AEON (AEON) CFO awarded 754,717 restricted stock units vesting over four years

Rhea-AI Filing Summary

Bencich John reported acquisition or exercise transactions in this Form 4 filing.

AEON Biopharma, Inc. reported that Chief Financial Officer John Bencich received a grant of 754,717 shares of Class A common stock in the form of restricted stock units. The award was granted on April 1, 2026 and carries no purchase price per share.

The restricted stock units vest in substantially equal installments on each of the first, second, third and fourth anniversaries of the grant date, contingent on continued service through each vesting date. Following this award, Bencich is shown as directly owning 754,717 shares of Class A common stock.

Insights

Equity Compensation Analyst

CFO receives multi-year RSU grant; routine equity compensation.

The filing shows AEON Biopharma’s CFO, John Bencich, receiving 754,717 restricted stock units of Class A common stock at a grant price of $0.00. This is compensation-related equity, not an open-market purchase or sale.

The RSUs vest in four substantially equal annual installments starting on the first anniversary of the April 1, 2026 grant date, conditioned on continued service. Such time-based vesting aligns the executive’s incentives with longer-term company performance, while spreading potential dilution over multiple years.

After this grant, Bencich’s direct holdings are 754,717 shares, with no derivative securities listed in this filing. The transaction is routine compensation rather than a directional bet on the stock, and there is no indication of a trading plan or related entity involvement in the disclosed footnote.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bencich John

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	754,717	$0.00	--

Holdings After Transaction: Class A Common Stock — 754,717 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

RSU grant size: 754,717 shares Grant price: $0.00 per share Total shares after transaction: 754,717 shares +2 more

5 metrics

RSU grant size 754,717 shares Restricted stock units of Class A common stock granted to CFO

Grant price $0.00 per share RSU grant on April 1, 2026

Total shares after transaction 754,717 shares Direct holdings following RSU award

Grant date April 1, 2026 RSU award grant date for CFO

Vesting schedule length 4 years Substantially equal installments on each of the first four anniversaries

Key Terms

restricted stock units, Grant Date, vesting date, beneficially owned, +1 more

5 terms

restricted stock units financial

"Represents an award of restricted stock units granted on April 1, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Grant Date financial

"granted on April 1, 2026 (the "Grant Date"), which vest"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

vesting date financial

"subject to continued service through the applicable vesting date"

beneficially owned financial

"total_shares_following_transaction": "754717.0000""

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bencich John

(Last) (First) (Middle)

C/O AEON BIOPHARMA, INC.

5 PARK PLAZA, SUITE 1750

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock(1)	04/02/2026		A		754,717	A	$0(1)	754,717	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents an award of restricted stock units granted on April 1, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.

	/s/ Alexander Wilson, as Attorney-in-Fact, for John Bencich	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AEON (AEON) CFO John Bencich receive in this Form 4 filing?

AEON Biopharma’s CFO John Bencich received an equity award of 754,717 restricted stock units of Class A common stock. The grant is compensation-based, carries a grant price of $0.00 per share, and results in direct ownership of 754,717 shares after the transaction.

When do the AEON (AEON) restricted stock units granted to the CFO vest?

The restricted stock units granted to AEON Biopharma’s CFO vest in substantially equal installments on the first, second, third, and fourth anniversaries of the April 1, 2026 grant date. Each installment is subject to the executive’s continued service through the applicable vesting date.

Is the AEON (AEON) CFO’s Form 4 transaction a stock purchase or sale?

The Form 4 for AEON Biopharma’s CFO reflects an acquisition through a grant of restricted stock units, coded as a compensation-related award. It is not an open-market stock purchase or sale, and no transaction price is shown beyond the $0.00 grant price.

How many AEON (AEON) shares does the CFO hold after this RSU grant?

Following the restricted stock unit grant, AEON Biopharma’s CFO is reported as directly owning 754,717 shares of Class A common stock. This figure reflects the total shares beneficially owned after the reported transaction in this Form 4 filing.

What conditions apply to the AEON (AEON) CFO’s RSU award vesting?

The AEON Biopharma CFO’s restricted stock unit award vests over four years in substantially equal annual installments. Vesting on each anniversary of the April 1, 2026 grant date is conditioned on the executive’s continued service through the respective vesting date.